Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Pescovitz

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2009
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus diseaseOriol Manuel, Anders Asberg, Xiaoli Pang, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 14, 2012
Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapyVincent C Emery, Oriol Manuel, Anders Asberg, et al.
Transplantation|October 27, 2009
Prospective observational study of sirolimus as primary immunosuppression after renal transplantationMark D Pescovitz, Nosratollah Nezakatgoo, Marc I Lorber, et al.
The Journal of Infectious Diseases|April 30, 2004
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipientsGuy Boivin, Nathalie Goyette, Christian Gilbert, et al.
Open Journal of Immunology|January 4, 2014
Total IgA and IgA reactivity to antigen I/II epitopes in HLA-DRB1*04 positive subjectsV Wallace McCarlie, James K Hartsfield, Janice S Blum, et al.
The Journal of Allergy and Clinical Immunology|September 13, 2011
Effect of rituximab on human in vivo antibody immune responsesMark D Pescovitz, Troy R Torgerson, Hans D Ochs, et al.
Transplantation|April 16, 2004
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokineticsCarlos A Vieira, Avinash Agarwal, Benita K Book, et al.
Clinical Pharmacokinetics|November 26, 2008
Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipientsBrenda C M de Winter, Teun van Gelder, Petra Glander, et al.
Journal of the American Society of Nephrology : JASN|March 26, 2002
Pancreas after kidney transplantationSundaram Hariharan, John D Pirsch, Christopher Y Lu, et al.
Transplantation|January 2, 2007
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantationHelio Tedesco-Silva, Mark D Pescovitz, Diane Cibrik, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2009
Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus diseaseOriol Manuel, Anders Asberg, Xiaoli Pang, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 14, 2012
Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapyVincent C Emery, Oriol Manuel, Anders Asberg, et al.
Transplantation|October 27, 2009
Prospective observational study of sirolimus as primary immunosuppression after renal transplantationMark D Pescovitz, Nosratollah Nezakatgoo, Marc I Lorber, et al.
The Journal of Infectious Diseases|April 30, 2004
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipientsGuy Boivin, Nathalie Goyette, Christian Gilbert, et al.
Open Journal of Immunology|January 4, 2014
Total IgA and IgA reactivity to antigen I/II epitopes in HLA-DRB1*04 positive subjectsV Wallace McCarlie, James K Hartsfield, Janice S Blum, et al.
The Journal of Allergy and Clinical Immunology|September 13, 2011
Effect of rituximab on human in vivo antibody immune responsesMark D Pescovitz, Troy R Torgerson, Hans D Ochs, et al.
Transplantation|April 16, 2004
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokineticsCarlos A Vieira, Avinash Agarwal, Benita K Book, et al.
Clinical Pharmacokinetics|November 26, 2008
Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipientsBrenda C M de Winter, Teun van Gelder, Petra Glander, et al.
Journal of the American Society of Nephrology : JASN|March 26, 2002
Pancreas after kidney transplantationSundaram Hariharan, John D Pirsch, Christopher Y Lu, et al.
Transplantation|January 2, 2007
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantationHelio Tedesco-Silva, Mark D Pescovitz, Diane Cibrik, et al.
Pageof 7